The purpose was to examine in mice the efficacy of various polymeric-encapsulated C5a peptidase vaccine formulations in eliciting a long-term immune response and preventing group B streptococcus (GBS) infection.
G
roup B streptococci are Gram-positive diplococci that produce polysaccharide capsules. 1 There are 10 different Group B Streptococcus (GBS) serotypes, based on the antigenic variation of the capsular polysaccharides. These serotypes are Ia, Ib, and II through IX. A recent international study most commonly isolated serotypes III and V from patients. 2 GBS can colonize the intestinal and urogenital tract of healthy adults without causing any complications. However, GBS infections can cause serious problems in pregnancy.
In 1985, the Institute of Medicine from the National Academies of Sciences indicated that a vaccine for GBS should be a high priority. In a 1999 report, they again listed a GBS vaccine for high-risk adults and pregnant women in the top tier for vaccine development. 3 They suggested the vaccine would have the greatest effect if given as part of routine prenatal care for all women in their first pregnancy. Maternal complications of GBS infections in pregnancy include urinary tract infections, chorioamnionitis, postpartum wound infection, pyelonephritis, postpartum endometritis, and sepsis. For the neonate, preterm premature rupture of membranes (PPROM), neonatal pneumonia, sepsis, meningitis, or death can occur as a consequence of GBS. [4] [5] [6] [7] [8] Because GBS infection continues to be a serious concern during pregnancy, the updated guidelines from the Centers for Disease Control and Prevention continue to recommend universal culturebased screening of all pregnant women at 35-37 weeks' gestation.
9, 10 Currently, if a pregnant woman screens positive for GBS, she will receive intravenous antibiotics during labor to prevent early-onset GBS disease in the child, which can include sepsis and death. 9 Recent studies demonstrate that up to 24% of all pregnant women receive antibiotic prophylaxis for GBS. Between 50% and 75% of neonates exposed through the birth ca-nal of GBS-infected mothers will be colonized.
Many shortcomings exist in the current therapy of antibiotic prophylaxis. These shortcomings are especially evident in cases in which a woman has a lack of prenatal care, delivers before being screened, delivers before the culture results return, has a rapid labor and does not finish receiving all of the antibiotic dose(s), or is allergic to antibiotics. In addition, the development of antibiotic resistance is an increasing problem.
Penicillin-tolerant strains of GBS have been identified, and resistance to other antibiotics has been documented. 8, 11 A recent study found 91% of strains isolated were resistant to erythromycin. 12 The consequences of a GBS infection in pregnancy require that treatment be given. However, this large-scale use of antibiotics is contributing to the development of antibiotic resistance. Without prevention strategies, such as vaccination, our first-line antibiotic therapies are going to become useless against GBS. Most importantly, this traditional approach does not prevent preterm delivery or PPROM or protect against lateonset disease caused by GBS infection. 13 A GBS vaccine could overcome these pitfalls.
Development of a vaccine for GBS has been hindered by several factors. First, there are 10 serotypes of GBS that are based on antigenic variation of the capsular polysaccharides. Purified capsular polysaccharides, without adjuvants, have elicited weak immune responses in vaccines, and a multivalent vaccine would be necessary to provide protection against the multiple GBS serotypes because each polysaccharide can target only the serotype from which it was derived. Furthermore, polysaccharide-based vaccines were unable to elicit significant mucosal immune responses. [14] [15] [16] A mucosal immune response would be critical in completely eliminating maternal GBS colonization. Eliminating colonization by all GBS serotypes would give the best chance of preventing the infection from being vertically passed to the child during the birthing process.
In the current study, we further evaluated the use of streptococcal C5a peptidase as the vaccine antigen. C5a peptidase is a highly conserved multifunctional surface protein that is expressed on the surface of all serotypes of both group A streptococcus (GAS) and group B streptococcus tested. [17] [18] [19] [20] C5a peptidase (ScpB) expressed by GBS is 98% identical in sequence to that expressed by GAS. 21, 22 Structurally, C5a peptidase contains 5 domains including a subtisilin-like protease domain, a protease-associated domain, and 3 fibronectin type III domains. 23 The enzymatic activity of the peptidase is highly specific for C5a, cleaving the chemotaxin at its polymorphonuclear leukocyte binding site. 24 Recent evidence also suggests that C5a peptidase may bind fibronectin to promote cellular invasion. 25, 26 Cheng et al 27 demonstrated that ScpB increased the immunogenicity of a GBS type III polysaccharide vaccine in mice when the 2 were coupled. In addition, the investigators found that ScpB was also found to induce the production of GBS serotypeindependent antibodies. 27 We have previously shown that encapsulating C5a peptidase within microspheres composed of a copolymer of lactic and glycolic acids, poly(lactide-coglycolide) (PLGA), was able to induce systemic and mucosal immune response in mice. Furthermore, this vaccine provided protection in mice against GBS serotype III in vaginal and pup challenge studies. 28 The PLGA polymer-based microspheres are able to act as an adjuvant to the vaccine and are safe for use in humans and has been used for many years in resorbable sutures, bone plates, and commercial depot drug delivery formulations. 29 The antigen release profile by PLGA microsphere-based vaccines is largely dependent on the lactide/glycolide ratio. Copolymers with a higher lactide/glycolide ratio have a longer degradation profile because lactic acid is hydrophobic. 30, 31 PLGA microspheres have been studied for use in numerous vaccines.
We hypothesized that encapsulation of C5a peptidase within PLGA microspheres would induce specific systemic and mucosal immune responses that would afford protection against multiple serotypes of GBS. We further hypothesized that differences in antigen doses (0, 10, and 30 g) and PLGA microsphere lactide-glycolide formulations (75:25 and 50:50) would affect these immune responses and the ability of vaccinated mice to prevent GBS colonization and to pass GBS protection to pups of vaccinated dams.
MATERIALS AND METHODS

C5a peptidase encapsulation
C5a peptidase, guanosine monophosphate prepared and greater than 98-99% pure, was generously provided by Pfizer (Groton, CT). The C5a peptidase was microencapsulated in PLGA microspheres. PLGA (50:50, inherent viscosity, 0.4 dL/g) and PLGA (75:25, inherent viscosity, 0.51 dL/g) were purchased from Lactel Absorbable Polymers (Cupertino, CA). Polyvinyl alcohol (PVA; 87-89% hydrolyzed, molecular weight 30-67,000 Da) was purchased from Sigma-Aldrich (St Louis, MO).
Encapsulation was done using a waterin-oil-in-water (w/o/w) double-emulsion technique as described previously. 16, 32, 33 Briefly, the internal aqueous phase consisted of 3.6 mg peptidase equivalent to 6.6 mg lyophilized powder C5a peptidase solubilized in 500 L of 1% (weight/volume) aqueous solution of PVA as a surfactant. This was emulsified into an oil phase containing 200 mg of PLGA 50:50 or PLGA 75:25 dissolved in 5 mL dichloromethane (DCM) using a microtip probe sonicator. This primary water/oil emulsion was then poured into 50 mL of external aqueous phase containing 1% (weight/volume) PVA as a surfactant and rapidly homogenized using a high-speed homogenizer at 9500 rpm for 30 seconds to form the secondary w/o/w emulsion. Stirring was then continued using a magnetic stirrer until complete evaporation of DCM. The microspheres were collected by centrifugation at 5000 ϫ g for 10 minutes, washed 3 times with deionized water, and lyophilized overnight.
To quantitate encapsulation efficiency of protein for dosing purposes, 30 mg of lyophilized PLGA microspheres containing C5a peptidase were dissolved in 3.0 mL of 1 M NaOH containing 5.0% (weight/volume) sodium dodecyl sulfate and incubated for 24 hours at room temperature. After centrifugation (4000 ϫ g for 10 minutes at room temperature), the supernatant was assayed for protein concentration using the bicinchonic acid assay (Thermo Scientific, Swedesboro, NJ) following the manufacturer's protocol. All the measurements were done in triplicate.
In vitro release profile
Thirty to 40 mg of C5a-peptidaseloaded PLGA microspheres were incubated in 2-3 mL phosphate buffered saline (PBS; pH 7.4). Two hundred microliters of samples were withdrawn at predetermined time intervals. The sample was centrifuged at 10,000 rpm for 5 minutes, and the supernatant was analyzed using a bicinchoninic assay to determine C5a content. The sedimented microspheres were dispersed in 200 L of PBS and replaced back instantly into the release samples. Scanning electron microscopy was performed as described previously at days 0 and 30 of the release profile assay.
28,32,33
Administration of vaccine
Female ICR mice (Charles River Breeding Laboratories, Portage, MI) 5-7 weeks old were vaccinated either through an intramuscular or intranasal route. For all doses of the intramuscular vaccine, the vaccine was administered in 100 L into the right upper leg. For all doses of the intranasal administration, 50 L of vaccine was administered into each nostril (100 L total volume). Booster doses were administered in the same manner as the initial vaccination and were given at weeks 4 and 8. For the pup challenge experiment, the vaccine was administered intranasally and boosters were given at weeks 2 and 4.
Determination of immune response
Mice were bled via the submandibular route at weeks 4, 8, 11, and 40. Serum was isolated using serum separator tubes (Becton Dickinson, Lincoln Park, NJ) per the manufacturer's recommendations, frozen, and stored at -80°C. Concurrently, vaginal washes were obtained by pipetting 100 L of PBS 40-50 times. Washes were frozen and stored at -80°C. Colormetric enzyme linked immunosorbant assay (ELISA) was used to measure the C5a peptidase-specific immunoglobulin (Ig) G and IgA antibody responses in serum and vaginal washes as described previously. 28 Samples producing a significant difference when further diluted are considered to have a larger immune response than samples in which a significant difference was observed in only smaller dilutions. The optical density (OD) 405 reading for each dilution was compared between each vaccine formulation group and the empty microsphere control. The largest dilution that remained statistically significant in the OD 405 comparisons was considered the titer. The largest dilution tested was 1:100,000. Animals were housed at the University of Iowa and all experiments were performed according to Institutional Animal Care and Use Committee-approved protocols.
Vaginal colonization studies
At 12 weeks, 1 ϫ 10 6 colony-forming units of GBS serotypes Ia, III, and V (ATCC 12400, 12403, and 700046, respectively, American Type Culture Collection, Manassas, VA) were pipetted into the vagina of 5 mice of each vaccination group. After 48 hours, vaginal washings were obtained and 2 dilutions were plated on blood agar plates. Plates were incubated for 24 hours at 37 o C with 5% CO 2 . After 24 hours, plates were assessed for growth of GBS. If no colonies were evident, plates were incubated for another 24 hours and growth of GBS colonies was again assessed. Cyclic adenosine monophosphate tests and Gram staining were used to determine whether questionable beta-hemolytic colonies were GBS. 34 The presence of at least 1 GBS colony on a plate was counted as a positive plate. Results of each vaccine group were compared against the group of mice receiving empty microspheres (75:25, 0 g).
Pup protection studies
At 48 hours of age, pups were injected with a 70% lethal dose of GBS serotype V (1.8 ϫ 10 7 colony-forming units) intraperitoneally. These pups were born to dams who received the 50:50 30 g for- 
Statistical analysis
Descriptive statistics described and compared the characteristics of our study 
RESULTS
Microsphere formulation
Both the C5a-loaded PLGA (50:50, 0.41 dL/g) microspheres and the C5a-loaded PLGA (75:25, 0.51 dL/g) microspheres exhibited a mean particle size of 3-4 m ( Figure 1, A and B) . There was no significant difference in the particle size of both the formulations. In terms of entrapment efficiency, the amount of C5a peptidase loaded per milligram of PLGA (50:50, 0.41 dL/g) was 12 g, whereas that of PLGA (75:25, 0.51 dL/g) was 16 g. The overall entrapment efficiency was about 65%. 
Immune response
To compare the strength and duration of C5a peptidase-specific IgG and IgA immune responses of mice vaccinated with various microsphere formulations and doses of encapsulated C5a peptidase, an ELISA was performed on serum and vaginal mucosal samples. When average titers were calculated regardless of route of administration, the 30 g doses of the 75:25 and 50:50 formulations elicited the highest titers at 40 weeks for C5a peptidase-specific IgG responses in serum and in vaginal washes (Figure 3 ). The 75:25 30 g dose led to the highest C5a peptidase-specific IgA titer at 40 weeks in serum and vaginal washes.
When we analyzed the C5a peptidasespecific antibody titers with respect to route of vaccine administration, we 
Release profile of antigen
The release profiles demonstrate an initial burst phase followed by a longer release of antigen. found that same results were achieved for mice vaccinated via the intramuscular route (Table 1 ). Titers of 1:100,000 were achieved by both 75:25 30 g and 50:50 30 g PLGA microspheres by 4 weeks and were sustained through 40 weeks for serum C5 peptidase-specific IgG, whereas the 75:25 10 g titer dropped to 1000 at 40 weeks.
In serum, the C5a-IgA response was not detectable for the 75:25 30 g dose until 8 weeks; by 11 weeks both the 75:25 30 g and 50:50 30 g doses were 1:100,000. By 40 weeks these serum titers were reduced to 1:10,000 for the 30 g doses and were not detectable for the 10 g dose. The vaginal C5a-specific titers were inconsistent.
The vaginal washes of mice inoculated with the 50:50 30 g and 75:25 30g vaccines had C5a-IgG titers of 1:100,000 at 40 weeks despite titers of 1:10,000 and 1:100 at 11 weeks, respectively. C5a peptidase-specific IgA antibodies were not detectable after 8 weeks in mice vaccinated with 75:25 10 g. However, at 40 weeks, the vaginal washes had titers of 1:100,000 and 1:10,000 with 75:25 30 g and 50:50 30 g, respectively.
Intranasal administration resulted in more variable titers (Table 2) . Each vaccine was able to generate a 1:100,000 C5a-IgG titer in serum by 4 weeks and sustain this titer through 11 weeks. However, all of the titers dropped by 40 weeks. Also in serum, the C5a-IgA titer reached the maximum dilution tested at 1:100,000 for all vaccines at week 8 and then dropped to 1:10,000 by week 11. In the vaginal washes, C5a-IgG titers of 1:100,000 were measured for each of the vaccine formulations at weeks 8 and 11, whereas the maximal 1:100,000 C5a-IgA titer was found only at week 8 in the vaginal wash samples.
Protection by immunization
In previous work, we demonstrated that the 50:50 30 g dose administered intranasally was able to prevent GBS colonization of the vaginal vault by serotype III. 28 We hypothesized that the 30 g doses of the 75:25 and 50:50 PLGA microsphere formulations would be able to protect against multiple serotypes of GBS. We used 15 mice from each group and inserted 1 ϫ 10 6 colony-forming units of serotypes Ia, III, and V (n ϭ 5 per serotype per vaccine group).
The results were compared against those from mice vaccinated with empty microspheres. Not all mice receiving empty microspheres were colonized (Table 3) . Without regard to which encapsulated vaccine the mice received, the mice that received a vaccine were significantly protected against colonization (27 of 90 positive) in comparison with mice that received the empty microspheres (18 of 30 positive) (P ϭ .005). The intramuscular 30 g doses of the 75:25 and 50:50 formulations were able to prevent colonization by serotypes 1a and III (0 of 5 positive) (Figure 4) . When all serotypes were considered together, the intranasal 30 g doses of the 75:25 and 50:50 PLGA microsphere formulations trended toward significantly inhibited vaginal colonization in mice (P ϭ .06).
We also tested mice that were vaccinated with unencapsulated antigen, and this vaccine did not significantly impede vaginal colonization (Table 3 ). Of note, most blood agar plates from mice that were colonized demonstrated colonies that were too numerous to count, often even in the smallest dilution plated, whereas in mice that were protected, the plates showed no evidence of GBS growth. Without being able to count colonies, it is impossible to perform statistical analysis based on the number of GBS colonies.
Because we did not observe any significant protection against serotype V in the vaginal colonization studies, we were interested in whether the IgG antibodies that cross the placenta in combination with any IgA antibodies in the dam's milk were able to afford protection to pups. Because we achieved high C5a-IgG titers in serum, we hypothesized that the C5a peptidase IgG antibodies that cross the placenta would be able to better protect pups than the weaker mucosal immune response that would be necessary to prevent vaginal colonization. In pup protection studies, pups were injected intraperitoneally with a 70% lethal dose of serotype V.
In comparing survival of pups between nonvaccinated (3 of 10) and vaccinated mice (4 of 5), we observed a notable higher (27) 100,000 (27) 100,000 (27) 1000 (11) . 
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survival for pups born to vaccinated dams (30% vs 80%). Although this was not a statistically significant difference (P ϭ .11) in a 2-tailed Fisher's exact test, we were limited by the number of female mice that bred within a similar time frame and by small litter sizes. However, these results were similar to the significant improvement in survival that we previously reported with serotype III.
28
COMMENT
In our previous work, we demonstrated that by encapsulating C5a peptidase withinmicrospherescomposedofPLGA,we were able to elicit antibody responses in serum and in the vagina of mice against GBS and that these responses were sufficient to protect against vaginal colonization by serotype III. 28 This protection was also conferred to pups of vaccinated dams. In this study, our primary objective was to determine the duration of the immune response to various vaccine formulations and doses. In addition, our secondary goal was to determine whether this univalent vaccine was able to protect against vaginal colonization by multiple serotypes of GBS. Furthermore, we wanted to compare whether different formulations of the PLGA microspheres vaccine (75:25 and 50:50) and different doses (0, 10, and 30 g) were more effective in protecting from vaginal colonization by GBS.
We achieved our main objective by determining whether there are differences in titers between vaccine formulations and doses. We have demonstrated that, in general, the 30 g doses of the 75:25 and 50:50 PLGA microsphere formulations generate the highest and most sustained C5a peptidase-specific IgG and IgA antibody responses. At weeks 4, 8, and 11, we did not detect any significant differences in the IgG or IgA titers between the PLGA 75:25 and 50:50 microsphere formulations at the 30 g dose.
At week 40, there were also no differences in the C5a peptidase-specific IgG responses. The titers were higher at week 40 for the 75:25 30 g vaccine compared with the 50:50 30 g vaccine. Because we measured similar particle sizes and we adjusted our dosing based on the actual amount of protein encapsulated, these factors cannot account for this difference. For additional consistency, the same volume was used to administer each vaccine. The slower degradation rate of PLGA 75:25 in comparison with PLGA 50:50 may affect the IgA titers over a longer time period.
Furthermore, we found that mice receiving the encapsulated C5a peptidase (including 75:25 10 g, 75:25 30 g, and 50:50 30 g) were significantly protected 
